Investors & Media

Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America

Companies jointly developing and commercializing eplontersen in the U.S.   AstraZeneca adds Latin America as part of its exclusive rights for rest of world CARLSBAD, Calif. , July 28, 2023 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) today announced it has expanded its existing

Read more
You are now leaving to visit